Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Swiss Nordic Bio 2020

Watch the video

Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

read more

Equity Research

Commissioned research by Vator Securities is offered to selected life science companies – "By Invitation Only". Commissioned researches are published continuously.

read more

Vator Securities Unicorn Summit was held on November 27th 2019 at IVA Conferens Center in Stockholm and was attended by over 200 guests.

Click here to watch the presentations

Vator Securities advises SciBase on 25 MSEK Rights Issue

Vator Securities acts as Financial Advisor in connection with the transaction raising SEK 25 million.

The capital raised in the rights issue will primarily be used to increase the market presence and penetration of SciBase in the US market where an FDA approval of Nevisense 3.0 is expected during the second quarter of 2020.

read more

Projektledare inom Corporate Finance till Vator Securities

Vator Securities växer och söker nu efter en projektledare med erfarenhet från Corporate Finance. Du erbjuds en utmanade och utvecklande tjänst i ett framgångsrikt bolag med högt driv och engagemang.

Du kommer att utgöra en viktig del av ett sammansvetsat team och få en unik möjlighet att utvecklas i takt med att bolaget växer ytterligare.

read more

Ascelia Pharma – A rocket roll out is the key to success

Ascelia Pharma has included the first patient in its pivotal, fully financed and an exceptionally straightforward phase III SPARKLE study with the lead asset Mangoral, targeting global launch in 2022.

We estimate a relatively high 75% likelihood that the imaging drug Mangoral will reach the market on the back of strong cumulative clinical data and a solid, straightforward Phase III design.

read more

Bio-Works Technologies – Leaving randomness

Bio-Works’s net sales for full year 2019 were SEK 5.6 million, down SEK 1 million from 2018. The decrease is due to the fact that the company’s largest customer in 2018 did not place an order in 2019.

In this update, we have looked beyond Bio-Works’s obvious stochastic character of the order inflow as we believe this is symptomatic for all early commercialization stage companies and not a structural problem for Bio-Works as such.

read more

More News